Bayer Raises Peak Sales Forecast for New-Medicine Portfolio

  • Five drugs have sales potential of more than $11 billion
  • Bayer sees Xarelto peak revenue climbing above $5.6 billion

Bayer AG raised the sales forecast for its latest blockbuster drugs, increasing optimism for the pharmaceutical unit as the German company pursues a $66 billion takeover of U.S. seeds giant Monsanto Co.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.